Advertisement
U.S. markets closed

ENDRA Life Sciences Inc. (NDRA)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
5.09-0.18 (-3.42%)
At close: 04:00PM EST
5.10 +0.01 (+0.20%)
After hours: 07:57PM EST

ENDRA Life Sciences Inc.

3600 Green Court
Suite 350
Ann Arbor, MI 48105-1570
United States
734 335 0468
https://endrainc.com

Sector(s)Healthcare
IndustryDiagnostics & Research
Full Time Employees21

Key Executives

NameTitlePayExercisedYear Born
Mr. Alexander Y. TokmanActing CEO & Chairman67.6kN/A1962
Mr. Michael Thornton Ph.D.Chief Technology Officer279.24kN/A1968
Dr. Jonathan Behr Ph.D.Co-FounderN/AN/AN/A
Mr. Richard JacrouxCFO & SecretaryN/AN/A1967
Mr. Steve FreemanHuman Resources LeaderN/AN/AN/A
Mr. Ziad RouagHead of Regulatory & Clinical AffairsN/AN/AN/A
Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

ENDRA Life Sciences Inc. develops technologies to improve the capabilities of clinical diagnostic ultrasound. The company is developing thermo-acoustic enhanced ultrasound technology that uses radio frequency pulses to generate ultrasonic waves in tissue to create high-contrast images for use in the treatment of nonalcoholic fatty liver disease, as well as in tissue composition, temperature monitoring, vascular imaging, and tissue perfusion. It has a collaborative research agreement with General Electric Company. ENDRA Life Sciences Inc. was incorporated in 2007 and is based in Ann Arbor, Michigan.

Corporate Governance

ENDRA Life Sciences Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.